相关临床试验
26
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
7.7%
已完成
9
34.6%
尚未招募
7
26.9%
招募中
4
15.4%
终止
3
11.5%
撤回
1
3.9%
暂无批准数据
- A groundbreaking radioactive therapy targeting the CDCP1 protein in cancer cells has begun its first human trial in Australia, with a 69-year-old Brisbane woman becoming the first patient to receive the treatment. - The therapy, developed over 24 years by Professor John Hooper, uses an innovative antibody that binds to CDCP1 found in ovarian, bladder, and other common cancers to deliver targeted radiotherapy. - Up to 45 patients with ovarian and bladder cancer will participate in the trial, which aims to provide exceptionally accurate imaging of metastasizing cancer and potentially become the gold standard treatment for multiple cancer types. - The research represents a collaboration between Mater Research, The University of Queensland, CSIRO, and other institutions, with ovarian cancer having a five-year survival rate of just 49 percent.
- University of Queensland researchers have identified DS90, the first nanobody capable of neutralizing both Nipah and Hendra viruses, for which no approved vaccines or cures currently exist. - The nanobody, derived from alpaca immune cells, can access deep viral pockets that traditional antibodies cannot reach and successfully blocks viral entry into cells. - Combining DS90 with existing m102.4 antibody therapy prevents Nipah virus from mutating and evolving, offering a powerful strategy to prevent deadly variants from emerging. - The discovery represents a crucial step toward developing clinical treatments for these fatal respiratory and neurological diseases that cause regular outbreaks in Asia and Australia.
